Request Your Free White Paper Now:

"Understanding Immunogenicity in AAV Gene Therapy"

Best Practices for Designing Robust Assays and Navigating Regulatory Pathways

As AAV-based gene therapies advance into clinical development, managing immunogenicity risk has become essential to ensuring patient eligibility, therapeutic durability, and regulatory approval. This expert-authored white paper delivers a practical, science-backed framework for building immunogenicity assays that are analytically rigorous, clinically relevant, and globally aligned.

Whether you’re designing early-phase protocols or preparing for global filings, this guide provides actionable insights to strengthen your assay strategy and advance your gene therapy program with confidence.

Topics covered:

• TAb vs. NAb Assays: In-depth comparison of formats, throughput, sensitivity, and translational relevance
• Assay Strategy Across Phases: Guidance on assay selection and validation from preclinical studies to CTA and companion diagnostic development
• Navigating Global Regulations: Insights into evolving regulatory expectations in the US (IDE, SRD, Q-submissions) and EU (IVDR)
• Validation Best Practices: Technical considerations for cutoff determination, reagent qualification, and global deployment
• Linking Immunogenicity & Efficacy: Approaches for integrating immune response data with therapeutic endpoints to refine patient stratification and study design

Download now.

Offered Free by: Precision for Medicine
See All Resources from: Precision for Medicine